T

Tennessee Center for Clinical Trials | Tullahoma, TN

Research site
(Unclaimed)
Location
1801 North Jackson Street Suite 100, Tullahoma, Tennessee, United States of America

Site insights

Top conditions

Top treatments

Olezarsen
sodium
Bococizumab
Neladenoson Bialanate
Istaroxime
PF-07265803
Mavacamten
Inclisiran
Tolvaptan
MYK-491

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 24 total trials

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Enrolling
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Enrolling
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic...

Active, not recruiting
Cardiomyopathy, Hypertrophic
Drug: Mavacamten
Other: Placebo

The purpose of the study is to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo in particip...

Active, not recruiting
Hypertriglyceridemia
Cardiovascular Diseases
Drug: Placebo
Drug: Olezarsen

The primary objective of this study is to evaluate the safety and tolerability of single and multiple doses at escalating dose levels of mRNA-0184.

Enrolling
Chronic Heart Failure
Drug: Placebo
Drug: mRNA-0184

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (C...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Olpasiran

This study aims to demonstrate superior efficacy and equivalent safety of the SELUTION SLR™ DEB 014 compared to plain (uncoated) balloon angioplasty...

Enrolling
Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities
Peripheral Arterial Disease
Device: SELUTION SLR™ DEB 014
Device: Plain (Uncoated) Balloon Angioplasty (PTA)

This study aims to demonstrate the safety and efficacy of the SELUTION SLR™ 018 DEB compared to plain (uncoated) balloon angioplasty in the treatment...

Enrolling
Superficial Femoral Artery Stenosis
Peripheral Arterial Disease
Device: Plain (Uncoated) Balloon Angioplasty (PTA)
Device: SELUTION SLR™ 018 DEB

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic...

Enrolling
Heart Failure
Other: Placebo
Drug: BMS-986435

This is a pilot, multinational, randomized, double-blind, placebo-controlled, 2-part safety and efficacy study. Subjects will consist of patients hos...

Active, not recruiting
Cardiogenic Shock
Drug: Istaroxime
Drug: Placebo

Trial sponsors

Bristol-Myers Squibb (BMS) logo
Pfizer logo
Amgen logo
Ionis Pharmaceuticals logo
M
Novartis logo
Bayer logo
Lilly logo
Moderna logo
Otsuka logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems